Lilly advances retatrutide toward sleep-apnea market

Eli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data in additional indications.

The push into sleep-apnea reflects Lilly's strategy to broaden the therapeutic reach of retatrutide beyond weight loss. While details on trial results are limited, the effort signals confidence in the molecule's versatility.

Industry observers note that expanding into sleep-apnea could open a sizable market, adding to the anticipation surrounding the upcoming obesity launch.